Isofol Medical AB (publ) announces that an abstract describing correlation between expression levels of folate-related genes in tumours with progression-free […]
The selected dose for the drug candidate arfolitixorin of 120 mg/m2, (approximately 200 mg for an adult male) is based
Isofol Medical AB (publ) today announce that the company will in the future be adopting the generic name arfolitixorin for
Isofol Medical AB (publ) has received positive feedback in scientific advice from the European Medicines Agency (EMA) regarding its candidate
The incentive program consisting of stock – and employee options in Isofol Medical AB, which was initiated in 2012 with
Prior to this year’s Gastrointestinal (GI) Cancers Symposium of the American Society of Clinical Oncology (ASCO), the worlds leading oncology
Isofol Medical AB (publ), developing Modufolin®(arfolitixorin) as treatment for advanced colorectal cancer, has had a successful regulatory meeting with the
Isofol Medical AB (publ), a clinical oncology company, reports efficacy data for Modufolin® (arfolitixorin) from patients treated during 16 weeks
Isofol Medical AB (publ), a clinical oncology company, announces that Chief Executive Officer Anders Rabbe and Chief Commercial Officer Sven
Isofol Medical AB (publ) announces that an abstract regarding Modufolins® efficacy in colorectal cancer treatment has been accepted for presentation
